GlaxoSmithKline: Shingles Treatment Meets Objective in Phase III Trial

Features Dow Jones Newswires

GlaxoSmithKline PLC (GSK.LN) Wednesday said a Phase III study of its shingles vaccine Shingrix showed a strong immune response in older adults, meeting its primary objective.

Continue Reading Below

Shares at 1309GMT, down 13 pence, or 0.8%, at 1,680 pence valuing the company at GBP82.62 billion

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

June 21, 2017 09:25 ET (13:25 GMT)